Romidepsin plus Liposomal Doxorubicin is Safe and Effective in Patients with Relapsed or Refractory T-cell Lymphoma: Results of a Phase I Dose-Escalation Study.
The histone deacetylase (HDAC) inhibitor romidepsin and the anthracycline liposomal doxorubicin (LD) have modest single-agent activity in cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). We investigated the safety and efficacy of the combination of these two agents in CTCL and PTCL. Using CTCL cell lines and primary CTCL tumor cells, we demonstrated synergistic anti-tumor activity with romidepsin plus doxorubicin. We then conducted a phase I dose-escalation study of the romidepsin/LD combination in relapsed/refractory CTCL and PTCL. The primary objective was to determine the maximum tolerated dose (MTD) of romidepsin in combination with LD at 20 mg/m2 IV, once every 28 days. Eleven CTCL and 12 PTCL patients were treated. The MTD of romidepsin was determined to be 12 mg/m2. Grade 3/4 hematologic toxicities included thrombocytopenia (17%), anemia (13%), and neutropenia (9%). The most frequent treatment-related non-hematologic adverse events were fatigue (48%), nausea (48%), vomiting (35%), and anorexia (30%). Among 21 evaluable patients, the overall response rate was 70% (1 CR, 6 PR) in CTCL and 27% (3 CR, 0 PR) in PTCL. Of the CTCL patients, 8 of 10 had skin response, including 6 patients (60%) achieving skin involvement < 10% of their body surface area at time of best response. Romidepsin plus LD demonstrated an acceptable safety profile and promising clinical efficacy with deep skin responses in relapsed/refractory CTCL. Thus, this combination could be considered as a bridge to skin-directed treatment or allogeneic hematopoietic cell transplantation in patients with aggressive CTCL.